Fathima, S., Rokach, L., Ghosoun, N., Rezasoltani, M., Alsugair, A., McCullough, K., Abdelmagid, M., Al-Kali, A., Alkhateeb, H., Begna, K., Mangaonkar, A., Matin, A., Saliba, A., Torghabeh, M. H., Litzow, M., Hogan, W., Shah, M., Patnaik, M., Pardanani, A., Badar, T., Murthy, H., Foran, J., Palmer, J., Punwani, N., Sproat, L., Khera, N., Yi, C. A., Tefferi, A., Gangat, N. (2025). CPX-351 versus venetoclax plus hypomethylating agents in newly diagnosed acute myeloid leukemia: A comparative analysis of outcomes in 600 patients. Blood. https://doi.org/10.1182/blood-2025-1602